Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients

Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients：An Open-label, Single-arm, Multicenter Phase I/II Study

This is a multicenter, open, single-arm, phase I/II study to evaluate the efficacy and safety of regorafenib plus raltitrexed as third-line treatment in patients with advanced colorectal cancer.

Study Overview

• Status: Not yet recruiting
• Conditions: Colorectal Neoplasms; Regorafenib; Raltitrexed; Third-line Treatment
• Intervention / Treatment: Drug: Regorafenib; Drug: Raltitrexed

Detailed Description

This is a multicenter, open, single-arm, phase I/II study to evaluate the efficacy and safety of regorafenib plus raltitrexed as third-line treatment in patients with advanced colorectal cancer.This Phase Ib/II study consists of two parts, Phase Ib, an open-ended, single-arm, multi-centre, dose-escalation study evaluating regorafenib, and Phase II, an open-label, multi-centre study evaluating the efficacy and safety of regorafenib in combination with raltitrexed.The primary study endpoint: progression-free survival (PFS).The secondary end endpoints include ORR (overall effectiveness of tumour treatment)，DCR (disease control rate)，3 month/6 month/9 month/12 month survival OS%，OS (overall survival)，incidence and severity of adverse events (AEs), serious adverse events (SAEs).

• Study Type: Interventional
• Enrollment (Anticipated): 50
• Phase: Phase 2; Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria

1. Sign a consent form
2. Age> 18 years
3. Pathological diagnosis as metastatic colorectal adenocarcinoma
4. Metastatic colorectal cancer with disease progression after 1st and 2nd line treatment；Received standard chemotherapy based on fluorouracil, oxaliplatin, irinotecan, patients are allowed to receive EGFR and/or VEGF inhibitors, patients are allowed to receive immunotherapy.
5. Measurable disease according to RECIST
6. ECOG score 0-1 points
7. Life expectancy ≥3 months
8. ALT and AST< 2.5 times the upper limit of normal (ULN), patients with liver metastases < 5 times ULN
9. Serum albumin ≥ 3.0g/ dL
10. Serum ALP <2.5 times ULN
11. Total bilirubin <l.5mg / dL
12. Estimated creatinine clearance (CLcr) ≥30mL/min as calculated using the Cockcroft-Gault equation
13. Lipase≤1.5x the ULN
14. Neutrophil absolute count (ANC) ≥1500/mm³, hemoglobin (Hb)>9g/dl, platelets> 10000/mm³
15. Pregnant or breastfeeding patients. (1) Women and men of childbearing potential must agree to use appropriate contraception prior to entering the program until at least 8 weeks after the last dose of study drug. The investigator or designee is required to advise the subject on how to achieve appropriate contraception. Adequate contraception is defined in the study as any medically recommended method (or combination of methods) according to standard treatment 2) Women of childbearing age must confirm a negative serum or urine pregnancy test within 7 days prior to initiating treatment and must agree to record a negative result prior to entering the study

Exclusion criteria.

1. Prior exposure to any VEGFR tyrosine kinase inhibitor (e.g., regorafenib, apatinib, anlotinib, furoquinitinib, etc.) therapy
2. Received raltitrexed in the previous treatment
3. Patients with abnormal coagulation function or those treated with thrombolytic or anticoagulant drugs with a tendency to bleed from the gastrointestinal tract, including active peptic ulcer with fecal occult blood ++, vomiting blood or black stool within 3 months
4. Prior or concurrent cancers with a different primary site or histology than CRC within the enrollment year, except cured in situ cervical cancer, non-melanoma skin cancer, and superficial bladder tumors: staged Ta, Tis, and T1
5. Arterial or venous thrombotic or embolic events such ascerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 month before the start of study medication (except for adequately treated catheter-related venous thrombos is occurring more than one month before the start of study medication)
6. Major surgery, biopsy or significant traumatic damage within 28 days prior to the start of investigational treatment
7. Non-healing wound, non-healing ulcer, or non-healing bone fracture.
8. Patients with brain metastases and/or cancerous meningitis
9. Congestive heart failure > New York Heart Association (NYHA) class 2.
10. Unstable angina (angina symptoms at rest), new onset angina (occurred within the last 3 months). Myocardial infarction within 6 months prior to the start of treatment.
11. Arrhythmias requiring antiarrhythmic therapy (beta-blockers or digoxin allowed)
12. Uncontrolled hypertension. (Systolic blood pressure > 150 mmHg or diastolic blood pressure > 90 mmHg despite optimal medical treatment)
13. Patients with pheochromocytoma
14. Pleural effusion or ascites causing restricted breathing (≥ CTCAE grade 2 dyspnea)
15. Known to have dihydropyrimidine dehydrogenase deficiency
16. Ongoing infection > Grade 2 NCI CTCAE
17. Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
18. Known hypersensitivity to any of the stidy drugs, study drug classes,or excipients in the formulation
19. The use of CYP3A4 inhibitors or inducers
20. Participation in another clinical trial within 4 weeks prior to enrollment and receipt of the investigational drug and any concomitant therapy containing the investigational drug
21. Received radiotherapy within 4 weeks prior to enrollment and the lesions observed in this study were in the target area of radiotherapy
22. Subjects with active tuberculosis (TB) who are on anti-tuberculosis treatment, or who have received anti-tuberculosis treatment within one year prior to screening
23. Comorbidities requiring long-term treatment with immunosuppressive drugs or systemic or topical corticosteroids at immunosuppressive doses (doses >10 mg/day of prednisone or other isotonic hormones)
24. Received any anti-infective vaccine (e.g., influenza vaccine, varicella vaccine, Neocon vaccine, etc.) within 4 weeks prior to enrollment
25. Pregnancy or breastfeeding
26. Persistent proteinuria >3.5g/24 hours by measuring the urine protein-creatinine ratio in random urine samples (grade 3, NCI-CTCAE version 5.0)
27. Positive for Human Immunodeficiency Virus (HIV)
28. Positive hepatitis B virus surface antigen (HBsAg) with positive HBV DNA copy number (quantitative test ≥ 1000 cps/ml)
29. Positive blood screen for chronic hepatitis C (positive for HCV antibodies)
30. Renal failure requiring hemodialysis or peritoneal dialysis
31. The degree of dehydration ≥ CTCAE version 5.0 level 1
32. Persons without legal capacity
33. Any other clinically significant disease or condition that, in the opinion of the investigator, could affect compliance with the protocol, or affect the subject's ability to sign an informed consent form (ICF), or is inappropriate for participation in this clinical trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Regorafenib combined with Raltitrexed; Regorafenib: 120mg/d，Po，qd,d1-d21，Every 4 weeks Raltitrexed: 3mg/㎡，ivgtt，d1，Every 3 weeks	Drug: Regorafenib; Regorafenib:120mg/d，Po，qd,d1-d21，Every 4 weeks; Other Names: Stivarga; Drug: Raltitrexed; Raltitrexed:3mg/㎡，ivgtt，d1，Every 3 weeks; Other Names: Sai wei jian

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-free Survival (PFS)	PFS, defined as the time from randomization to the first occurrence of disease progression as determined by the investigator with use of RECIST v1.1 or death from any cause, whichever occurs first.	one year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival (OS)	Duration from the date of initial treatment to the date of death due to any cause.	two years
Objective Response Rate (ORR)	ORR, determined using RECIST v1.1, defined as best overall response (CR or PR) across all assessment time points during the period from enrolment to termination of trial treatment.	one year
Disease Control Rate (DCR)	Determined using RECIST v1.1 criteria.	one year
Incidence and severity of adverse events (AE) and serious adverse events (SAE)	Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0.	two years

Collaborators and Investigators

• Sponsor: China Medical University, China
• Collaborators: The People's Hospital of Liaoning Province; The First Affiliated Hospital of Dalian Medical University; The Second Affiliated Hospital of Dalian Medical University; Anshan Tumor Hospital; Benxi Cental Hospital

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): July 1, 2022
• Primary Completion (ANTICIPATED): July 1, 2025
• Study Completion (ANTICIPATED): December 30, 2025

Study Registration Dates

• First Submitted: June 16, 2022
• First Submitted That Met QC Criteria: June 16, 2022
• First Posted (ACTUAL): June 22, 2022

Study Record Updates

• Last Update Posted (ACTUAL): June 29, 2022
• Last Update Submitted That Met QC Criteria: June 24, 2022
• Last Verified: June 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Folic Acid Antagonists; Raltitrexed
• Other Study ID Numbers: REGORAL

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No